Join
Live feed
·
PRReleasevia Quantisnow
Sinovac Biotech, Ltd. logo

SINOVAC Initiated a Phase III Clinical Trial on Bivalent Vaccine Against Hand Foot and Mouth Disease (HFMD)

ByQuantisnow·Wall Street's wire, on your screen.
SVA· Sinovac Biotech, Ltd.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track SVA (Sinovac Biotech, Ltd.) and more on Quantisnow.